'Cipla in talks to buy Hetero Drugs' US biz'

BS Reporter Mumbai
Last Updated : Sep 04 2015 | 12:49 AM IST
Drug maker Cipla is in talks to acquire Hetero Drugs' US business, a media report said on Thursday. The deal values the US business at $500-550 million and will give Cipla access to generic drug portfolio and abbreviated new drug application pipeline, the report said.

US business accounts only eight per cent of Cipla's revenue and the company is keen to expand the share. If the deal fructifies it will be the second large acquisition by an Indian company in US in two months.

"Cipla does not comment on any product or partner discussions. As a pharmaceutical company, we are constantly in discussions with multiple parties on potential collaboration opportunities - in line with our aspiration to drive access and ensure availability of high quality, affordable medicines," a company spokesperson said.

Cipla Global Chief Executive Subhanu Saxena had said last week that the company's future growth will largely be organic and added the firm was not under any compulsion to do mega acquisitions.

He added the firm would continue with its strategy of developing joint ventures with pharmaceutical firms in other countries.


*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 04 2015 | 12:41 AM IST

Next Story